Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Industrial Info
The efficacy of SGLT-2 inhibitors for cardiovascular events has been more widely confirmed
2018-06-12
来源：亚科官网
Key words: Type 2 diabetes, Sodium glucose cotransporter-2 inhibitor, SGLT-2, Cardiovascular disease risk
Recently, Kosiborod M. et al. [1] have published a paper entitled "Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study" in the journal J. Am. Coll. Cardiol. (JACC). The research shows that: sodium glucose cotransporter-2 inhibitor (SGLT-2i) can reduce the risk of cardiovascular disease in patients with type 2 diabetes.
.jpg)
Type 2 diabetes is the most common type of diabetes in the world. Cardiovascular disease is the leading cause of death in people with diabetes. The risk of cardiovascular disease in patients with type 2 diabetes is twice that of nondiabetic people. SGLT-2 inhibitors are the most popular targets for research in addition to DPP-4 inhibitors in recent years. They are specific in renal tubular cells and block the reabsorption of glucose in the kidneys, passing excessive glucose through the urine to achieve the effect of lowering blood glucose levels.
Previous studies [2] have confirmed that SGLT-2 inhibitors can reduce the risk of cardiovascular and heart failure in patients with type 2 diabetes, but it is limited to the risk of heart failure and death, and the population is limited to European and American. In the latest study, researchers conducted a more extensive assessment of the effects of SGLT-2 inhibitors on cardiovascular disease risk in diabetic patients in six countries: Korea, Japan, Singapore, Israel, Australia, and Canada. The results of the analysis showed that SGLT-2 inhibitors were associated with a lower risk of death, a lower hospitalization rate of heart failure, a lower risk of MI, and a lower risk of stroke than other hypoglycemic agents. And this result is consistent in different countries and with or without cardiovascular disease.
Current globally marketed SGLT-2 inhibitors include Canagliflozin, Dapagliflozin, Empagliflozin, Ipragliflozin, Tofogliflozin, Luseogliflozin and Ertugliflozin. We hope that these drugs will provide new choices for people with diabetes and which will effectively change their quality of life and prolong their lives.
References
[1] Mikhail K. et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs——The CVD-REAL 2 Study. JACC. 2018 doi: 10.1016/j.jacc.2018.03.009.
[2] James L., Januzzi Jr., Javed Butler, Petr Jarolim, et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. JACC. 2017, doi: 10.1016/j.jacc.2017.06.016.
Related Links: The Mechanism and Common Drugs of DPP-4 Inhibitors
Edited by Suzhou Yacoo Science Co., Ltd.
